Chronic kidney disease in people with type 2 diabetes is heavily prevalent, and the main causes are diabetes and hypertension. In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss the health burden of chronic kidney disease (CKD) in people with type 2 diabetes, SGLT-2 inhibitors and their role in improving renal outcomes, and the clinical evidence that supports their use in people with CKD with or without diabetes.
The abstract entitled: ‘Go with the Flozin: Clinical Implications of SGLT-2 Inhibitors for Chronic Kidney Disease’
was presented at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, 12-15 Aug, 2022.
- Could you give us a brief overview of the health burden of chronic kidney disease (CKD) in people with type 2 diabetes (T2D)?
- What is the mechanism of action of SGLT-2 inhibitors in improving renal outcomes in T2D?
- What clinical evidence supports the use of SGLT-2 inhibitors in people with CKD with or without diabetes?
- How widespread is the use of SGLT-2 inhibitors in clinical practice?
- How can we optimize the use of SGLT-2 inhibitors?
Disclosures: Speaker’s bureau participant with Novo Nordisk on semaglutide.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ADCES 2022
Click here for more related content.
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research highlights in diabetes and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of diabetes? (0:16) What are the hot topics and […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!